7. Drug updates

Cannabis derived drug for type 2 diabetes

Findings from a randomized, double-blind, placebo-controlled phase 2a trial investigating two different phytocannabinoids in type 2 diabetes patients suggest that a nonpsychoactive analog of a cannabis component may represent a new agent for treating type 2 diabetes. Unlike the related — and better-known — cannabis constituent tetrahydrocannabinol (THC), cannabidiol (CBD) and tetrahydrocannabivarin (THCV) don't activate CB1receptors in the brain and therefore lack the psychotropic actions of THC.

A total 62 subjects with non–insulin-treated type 2 diabetes were randomized to one of five treatment arms: CBD (100 mg twice daily), THCV (5 mg twice daily), 1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily), 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily), or matched placebo for 13 weeks. Fasting plasma glucose was lower with THCV from baseline compared with placebo, from about 133 mg/dL to 121 mg/dL (P < .05), along with a significant concurrent increase in beta-cell function (P < .01). Adverse events were reported by majorities of all groups, including placebo, and were mostly mild to moderate.

Read More

Semaglutide proven beneficial for heart

In the SUSTAIN 6 study results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016 and also published in the New England Journal of Medicine, Semaglutide significantly reduced the risk of the primary composite endpoint of time to first occurrence of either cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 26% vs placebo, when added to standard of care in 3,297 adults with type 2 diabetes at high CV risk. there was a significant 39% decrease in non-fatal stroke and a non-significant 26% decrease in non-fatal myocardial infarction and a neutral outcome (2% decrease) in CV death after only two years of treatment.

SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a clinical programme for semaglutide, administered once-weekly, that comprises six phase 3a global clinical trials encompassing more than 7,000 adults with type 2 diabetes as well as two Japanese trials encompassing around 1,000 adults with type 2 diabetes. Semaglutide is a once-weekly investigational analogue of human glucagon-like peptide-1 (GLP-1).

Read More


FDA has approved MiniMed 670G system – the first hybrid closed loop system in the world. MiniMed 670G system features the most advanced algorithm – SmartGuard that enables greater glucose control with reduced user input.

The system delivers a variable rate of insulin 24 hours a day based on the personalized needs of the individual, maximizing the time glucose levels are within the target range.The system uses new Guardian Sensor 3, our most advanced and accurate glucose sensor which is the first and only sensor approved by the FDA to control a hybrid closed loop system.

Read More

FDA Approves FreeStyle LibrePro

The US Food and Drug Administration (FDA) has approved the FreeStyle Libre Pro System, developed by Abbott, a continuous glucose monitoring technology for use in diabetes patients. With the FreeStyle Libre Pro system there is no requirement for fingerstick calibration.The sensor performs a reading every fifteen minutes and can run continuously for up to 14 days.

Read More

Previous | Home | Next

This newsletter is published for free distribution through the Internet for doctors, patients and public for promoting healthy lifestyles.
For enquiries info@jothydev.net.
Please visit: jothydev.net | research.jothydev.com | diabscreenkerala.net | jothydev.com/newsletter